First Trust Exchange-Traded Fund III First Trust SMID Growth Strength ETF FSGS 深 沪
已收盘 08-01 16:00:00 美东时间
30.0292
-0.390
-1.28%
华盛通- 最 高30.0292
- 今 开29.95
- 成交量 718股
- 最 低 30.0292
- 昨 收 30.4191
- 总市值 3002.92万
- 52周最高 32.5669
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 24.39
- 委 比 -66.67%
- 总股本 100.00万
- 历史最高 32.5669
- 量 比 0.49
- 振 幅 0.00%
- 历史最低 9.9631
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ZyVersa Therapeutics Releases Mid-Year Shareholder Letter Highlighting Recent Corporate Developments And R&D Progress Including Closing Two Financial Transactions Providing Access To $12M In Capital
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have
07-21 20:04
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and regulatory momentum.
07-09 01:48
Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews
During the last three months, 8 analysts shared their evaluations of Travere Th...
07-02 05:01
7 Analysts Assess Travere Therapeutics: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 7 analysts h...
06-11 20:00
Travere Therapeutics Reports SPARTACUS And PROTECT OLE Data Showing FILSPARI's Proteinuria Reduction And IgA Protection
Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2iNew mechanistic data to show FILSPARI protects against
06-04 04:33
Travere Therapeutics Receives FDA Acceptance Of Supplemental New Drug Application For FILSPARI In FSGS
PDUFA target action date of January 13, 2026If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure
05-16 04:09
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025
Earnings Call Insights: Travere Therapeutics (TVTX) Q1 2025 Management View CEO Eric Dube reported strong progress for the quarter, highlighting FILSPARI's foundational role in treating IgA nephropath...
05-02 11:08
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
Across the recent three months, 8 analysts have shared their insights on Traver...
04-24 05:00
Travere Therapeutics Announces It Will Present Three Abstracts, Including One Late-Breaking Oral Presentation, At Upcoming National Kidney Foundation Spring Clinical Meetings 2025, Taking Place April 10-13 In Boston, MA
Late-breaking oral presentation details partial and complete proteinuria remission data from the DUPLEX Study of FILSPARI in FSGSData presentations highlight SPARTAN Study results and real-world case studies of FILSPARI
04-01 04:35
Analyst Expectations For Travere Therapeutics's Future
Travere Therapeutics (NASDAQ:TVTX) has been analyzed by 5 analysts in the last ...
02-25 06:02
